Trifluoroacetic Acid
Trifluoroacetic acid is a corrosive organofluorine compound that is structurally analogous to, but stronger than, acetic acid. Available in various quantities and reagent grades, it is used in NMR spectroscopy, mass spectrometry, organic synthesis, etc.
Almost 100,000-fold more acidic than acetic acid, TFA is widely used in organic chemistry. TFA is used as a reagent in organic synthesis because of its properties: volatility, organic solvent solubility, and acidic strength. It is less oxidizing than sulfuric acid and is more readily available in its anhydrous form than some other acids . Other features include:
- Used in acid-catalyzed reactions, especially peptide synthesis (to cleave esters)
- Dissolves protein when mixed with liquid SO2
- Removes t-butyl derived side-chain protecting groups in Fmoc peptide synthesis
- Can remove the t-butoxycarbonyl protecting group in organic synthesis
- At low concentrations, acts as an ion-pairing agent for peptides and small proteins in organic compound liquid chromatography
- For acid-stable materials, can be a solvent for NMR spectroscopy
- Acts as a calibrant in mass spectrometry
- Used to produce trifluoroacetate salts
- An ingredient in adhesives, sealants, paints, and coatings
When TFA combines with bases and metals, especially light metals, a strong exothermic reaction occurs. When mixed with lithium aluminum hydride (LAH), the reaction is explosive.
Although nonflammable, TFA is corrosive to skin, eyes, and mucous membranes and requires careful use and handling. It is harmful when inhaled, causes severe skin burns and eye damage, and is toxic to aquatic organisms at even low concentrations.
TFA is also a product of the metabolic breakdown of the anesthetic agent halothane. It is the suspected cause of halothane-induced hepatitis.
Medchemexpress LLC Astax-35r TFA | 99.1% | 2392.86 | 5 MG
aStAx-35R TFA is a stapled peptide that antagonizes the nuclear form of β-catenin and inhibits Wnt signaling. It competitively inhibits the binding of β-catenin to TCF4 and selectively induces growth inhibition of Wnt-dependent cancer cells.
- Antagonizes nuclear form of β-catenin.
- Inhibits Wnt signaling.
- Competitively inhibits the binding of β-catenin to TCF4.
- Selectively induces growth inhibition of Wnt-dependent cancer cells.
Medchemexpress LLC Cppi9 Tfa | 99.9% | 1553.37 | 5 MG
CPP9 TFA is a small, amphipathic, cyclic cell-penetrating peptide (CPP) that binds directly to plasma membrane phospholipids and enters mammalian cells via endocytosis. Its efficient release from the endosome after cellular entry makes it suitable for intracellular delivery of therapeutic agents and chemical probes.
- Efficient release from endosome after cellular entry
- Suitable for intracellular delivery of therapeutic agents
- Suitable for intracellular delivery of chemical probes
- For research use only
Medchemexpress LLC CMD178 TFA | 99.7% | 964.05 | 5 MG
CMD178 (TFA) is a lead peptide that consistently reduces the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Ra signaling. It also acts as an inhibitor of STAT5 and inhibits Treg cells development.
- Reduces expression of Foxp3 and STAT5 induced by IL-2/s IL-2Ra signaling
- Inhibits STAT5
- Inhibits Treg cells development
Medchemexpress LLC Ribupatide TFA | 2940971-65-1 | 99.8% | 4907.48 | 1 MG
Ribupatide TFA is a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. It is orally active and can also be administered by injection, making it suitable for antidiabetic research.
- Dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist
- Can be studied in antidiabetic research
- Orally active
- Can also be administered by injection
Medchemexpress LLC L-Serine, L-alanyl-L-prolyl-L-prolyl-L-histidyl-L-alanyl-L-leucyl- (TFA) | 99.87% | 805.80 | 25 MG
RS 09 TFA is an LPS peptide mimic and a TLR4 agonist. It binds to TLR-4, activating NF-κB, and functions as an adjuvant in vivo to enhance the antigen-specific immune response.
- Acts as an LPS peptide mimic and TLR4 agonist.
- Binds to TLR-4 and activates NF-κB.
- Enhances antigen-specific immune response in vivo.
- Stimulates TLR-4 and activates NF-κB in HEK-BLUETM-4 cells.
- Induces nuclear translocation of NF-κB and secretion of inflammatory cytokines in RAW264.7 cells.
Medchemexpress LLC Sar441255 TFA | 99.93% | 4866.56 (free base) | 5 MG
SAR441255 TFA is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. It displays high potency with balanced activation of all three target receptors and shows positive acute glucoregulatory effects in diabetic obese monkeys. This product is for research use only.
- Potent unimolecular peptide
- GLP-1/GIP/GCG receptor triagonist
- Displays high potency
- Balanced activation of target receptors
- Shows positive acute glucoregulatory effects
- For research use only
Medchemexpress LLC PBX-7011 TFA | 98.6% | 561.46 | 25 MG
PBX-7011 TFA is a derivative of camptothecin that exhibits anticancer activity. It functions by inhibiting the expression of cancer-related survival genes, specifically DDX5, Survivin, Mcl-1, and XIAP, in FaDu cells. Additionally, it degrades DDX5 proteins.
- Derivative of camptothecin.
- Inhibits expressions of cancer related survival genes DDX5, Survivin, Mcl-1, and XIAP in FaDu cells.
- Degrades DDX5 proteins.
- Exhibits anticancer activity.
Medchemexpress LLC SJ1008030 TFA | 2863634-97-1 | 99.8% | 987.96 | 1 MG
SJ1008030 TFA is a JAK2 PROTAC designed for selective degradation of JAK2. This compound inhibits MHH-CALL-4 cell growth and is suitable for leukemia research. It degrades JAKs, GSPT1, and IKZF1 in a dose-dependent manner, indicating inhibition of the JAK-STAT signaling pathway.
- Selectively degrades JAK2
- Inhibits MHH-CALL-4 cell growth with an IC50 of 5.4 nM
- Can be used for leukemia research
- Degrades JAKs, GSPT1, and IKZF1 in a dose-dependent manner
- Indicates inhibition of the JAK-STAT signaling pathway
Medchemexpress LLC Ncgc00138783 TFA | 00-00-0 | 99.4% | 617.62 g·mol⁻¹ | C28H27F4N7O3S | 5 MG
NCGC00138783 TFA is a small-molecule inhibitor that selectively targets the CD47/SIRPα immune checkpoint, blocking the CD47-SIRPα interaction with reported in vitro activity (IC50 ≈ 50 μM). Supplied as the trifluoroacetic acid (TFA) salt for research applications.
- Selective inhibitor of the CD47/SIRPα immune checkpoint.
- Reported IC50 approximately 50 μM in biochemical assays.
- Supplied as the trifluoroacetic acid (TFA) salt.
- High purity (99.4%).
- Molecular weight 617.62 g·mol⁻¹.
- Store at 4 °C; protect from moisture and light.